Mature Survival Results with Preoperative Cisplatin, Protracted Infusion 5-FU, and 45 GY Radiotherapy for Esophageal Cancer

Diana Stripp, MD
University of Pennsylvania Cancer Center
Ultima Vez Modificado: 5 de noviembre del 2001

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

ASTRO: Cisplatin Plus RT, HDRB Beneficial for Cervical Cancer

Oct 4, 2013

Disease-free survival up with chemoradiotherapy, high-dose-rate brachytherapy in stage IIIB disease

Pre-Op Regimen Tolerable for Esophageal Adenocarcinoma

Oct 25, 2011

But fails to meet objective of achieving pathologic complete response of 40 percent

ASTRO: New Chemo, Radiation Combo Suggested in Rectal Cancer

Oct 4, 2011

Patients have 88 percent chance of survival at three years with capecitabine, radiation at 50 Gy